Stephen A. Strickland

7.8k total citations · 1 hit paper
99 papers, 2.4k citations indexed

About

Stephen A. Strickland is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Stephen A. Strickland has authored 99 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Hematology, 41 papers in Molecular Biology and 30 papers in Genetics. Recurrent topics in Stephen A. Strickland's work include Acute Myeloid Leukemia Research (77 papers), Chronic Myeloid Leukemia Treatments (22 papers) and Acute Lymphoblastic Leukemia research (21 papers). Stephen A. Strickland is often cited by papers focused on Acute Myeloid Leukemia Research (77 papers), Chronic Myeloid Leukemia Treatments (22 papers) and Acute Lymphoblastic Leukemia research (21 papers). Stephen A. Strickland collaborates with scholars based in United States, Germany and Australia. Stephen A. Strickland's co-authors include Michael R. Savona, Tara L. Lin, Gail J. Roboz, Roland B. Walter, Walter Fiedler, Andrew H. Wei, Anoop Enjeti, John Hayslip, Kaffa Fakouhi and Brenda Chyla and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Stephen A. Strickland

97 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

2019 456 citations Andrew H. Wei, Stephen A. Strickland et al. Journal of Clinical Oncology profile →

Peers

Stephen A. Strickland

HEMAT

ONCOL

GENET

PHEOH

Agnieszka Wierzbowska Poland

Alan K. Burnett United Kingdom

Sören Lehmann Sweden

Mario Tiribelli Italy

Brian A. Jonas United States

Yesid Alvarado United States

Fumihiko Hayakawa Japan

Alice S. Mims United States

Todd M. Zimmerman United States

Heather Oakervee United Kingdom

Agnieszka Wierzbowska Poland

Stephen A. Strickland

1.5k ×0.8

HEMAT

1.1k ×0.8

483 ×1.0

ONCOL

461 ×1.0

GENET

435 ×1.1

PHEOH

Citations per year, relative to Stephen A. Strickland Stephen A. Strickland (= 1×) peers Agnieszka Wierzbowska

Countries citing papers authored by Stephen A. Strickland

Since Specialization

Citations

This map shows the geographic impact of Stephen A. Strickland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen A. Strickland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen A. Strickland more than expected).

Fields of papers citing papers by Stephen A. Strickland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen A. Strickland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen A. Strickland. The network helps show where Stephen A. Strickland may publish in the future.

Co-authorship network of co-authors of Stephen A. Strickland

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen A. Strickland. A scholar is included among the top collaborators of Stephen A. Strickland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen A. Strickland. Stephen A. Strickland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pullarkat, Vinod, Mark J. Levis, James A. McCloskey, et al.. (2025). V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML. PubMed. 2(4). 100123–100123. 1 indexed citations

Daver, Naval, Abhishek Maiti, David A. Sallman, et al.. (2024). A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify).. Journal of Clinical Oncology. 42(16_suppl). TPS6586–TPS6586. 5 indexed citations

Perl, Alexander E., Naoko Hosono, Pau Montesinos, et al.. (2022). Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Blood Cancer Journal. 12(5). 84–84. 27 indexed citations

Strickland, Stephen A. & Norbert Vey. (2022). Diagnosis and treatment of therapy-related acute myeloid leukemia. Critical Reviews in Oncology/Hematology. 171. 103607–103607. 46 indexed citations

Ryan, Daniel, Laura F. Newell, Ellen K. Ritchie, et al.. (2020). Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis. Biology of Blood and Marrow Transplantation. 26(3). S9–S10. 1 indexed citations

Byrne, Michael, Salyka Sengsayadeth, Katie S. Gatwood, et al.. (2020). The use of venetoclax‐based salvage therapy for post‐hematopoietic cell transplantation relapse of acute myeloid leukemia. American Journal of Hematology. 95(9). 1006–1014. 44 indexed citations

Wei, Andrew H., Stephen A. Strickland, Jing-Zhou Hou, et al.. (2019). Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Journal of Clinical Oncology. 37(15). 1277–1284. 456 indexed citations breakdown →

Moyo, Tamara K., Justin M. Watts, Barry Skikne, et al.. (2019). Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition. Blood. 134(Supplement_1). 4236–4236. 10 indexed citations

Ryan, Daniel, Laura F. Newell, Ellen K. Ritchie, et al.. (2019). Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis. Blood. 134(Supplement_1). 3842–3842. 1 indexed citations

10.

DeAngelo, Daniel J., Alison R. Walker, Richard F. Schlenk, et al.. (2019). Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. Leukemia Research. 85. 106197–106197. 16 indexed citations

11.

Martin, Thomas G., Stephen A. Strickland, Martha Glenn, et al.. (2019). Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma. Blood Cancer Journal. 9(4). 41–41. 70 indexed citations

12.

Ramsey, Haley E., Melissa A. Fischer, Taekyu Lee, et al.. (2018). A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discovery. 8(12). 1566–1581. 254 indexed citations

13.

Strickland, Stephen A., Aaron C. Shaver, Michael Byrne, et al.. (2018). Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia. Leukemia Research. 65. 67–73. 10 indexed citations

14.

Strickland, Stephen A., Zhuoxin Sun, Rhett P. Ketterling, et al.. (2017). Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials. Leukemia Research. 59. 55–64. 13 indexed citations

15.

Zhao, Yue, Qi Liu, Pankaj Acharya, et al.. (2016). High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML. Cell Reports. 16(7). 2003–2016. 59 indexed citations

16.

Jamieson, Gene C., Judith A. Fox, Ming Poi, & Stephen A. Strickland. (2016). Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia. Drugs. 76(13). 1245–1255. 27 indexed citations

17.

Levis, Mark J., Alexander E. Perl, Jessica K. Altman, et al.. (2015). Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).. Journal of Clinical Oncology. 33(15_suppl). 7003–7003. 30 indexed citations

18.

Sengsayadeth, Salyka, Madan Jagasia, Barbara Engelhardt, et al.. (2012). Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers. Bone Marrow Transplantation. 47(12). 1535–1537. 51 indexed citations

19.

Strickland, Stephen A., Anastasios Raptis, James Rutledge, et al.. (2012). Correlation of the microculture-kinetic drug-induced apoptosis assay with patient outcomes in initial treatment of adult acute myelocytic leukemia. Leukemia & lymphoma. 54(3). 528–534. 9 indexed citations

20.

O’Donnell, Margaret, Jessica K. Altman, Frederick R. Appelbaum, et al.. (2011). Acute Myeloid Leukemia. Journal of the National Comprehensive Cancer Network. 9(3). 280–317. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact